These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8104695)

  • 1. Interferon-gamma-induced increased sensitivity of HER2/neu-overexpressing tumor cells to lymphokine-activated killer cell lysis: importance of ICAM-1 in binding and post-binding events.
    Fady C; Gardner A; Gera JF; Lichtenstein A
    Cancer Immunol Immunother; 1993 Oct; 37(5):329-36. PubMed ID: 8104695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance of HER2/neu-overexpressing tumor targets to lymphokine-activated-killer-cell-mediated lysis: evidence for deficiency of binding and post-binding events.
    Fady C; Gardner A; Gera JF; Lichtenstein A
    Cancer Immunol Immunother; 1993 May; 36(5):307-14. PubMed ID: 8097427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-induced increase in sensitivity of ovarian cancer targets to lysis by lymphokine-activated killer cells: selective effects on HER2/neu-overexpressing cells.
    Fady C; Gardner AM; Gera JF; Lichtenstein A
    Cancer Res; 1992 Feb; 52(4):764-9. PubMed ID: 1346583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased susceptibility of IFN-gamma-treated neuroblastoma cells to lysis by lymphokine-activated killer cells: participation of ICAM-1 induction on target cells.
    Naganuma H; Kiessling R; Patarroyo M; Hansson M; Handgretinger R; Grönberg A
    Int J Cancer; 1991 Feb; 47(4):527-32. PubMed ID: 1671670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of leukemic cell sensitivity to lymphokine-activated killer cytolysis: role of intercellular adhesion molecule-1.
    Triozzi PL; Eicher DM; Smoot J; Rinehart JJ
    Exp Hematol; 1992 Oct; 20(9):1072-6. PubMed ID: 1361453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intercellular adhesion molecule-1 expression by bladder cancer cells: functional effects.
    Campbell SC; Tanabe K; Alexander JP; Edinger M; Tubbs RR; Klein EA
    J Urol; 1994 May; 151(5):1385-90. PubMed ID: 7908992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of adhesion molecules in lymphokine-activated killer cell killing of bladder cancer cells: further evidence for a third ligand for leucocyte function-associated antigen-1.
    Jackson AM; Alexandrov AB; Prescott S; James K; Chisholm GD
    Immunology; 1992 Jun; 76(2):286-91. PubMed ID: 1353063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine regulation of cell-to-cell interactions in lymphokine-activated killer cell cytotoxicity in vitro.
    Takahashi T; Ishikura H; Iwai K; Takahashi C; Kato H; Tanabe T; Yoshiki T
    Cancer Immunol Immunother; 1993; 36(2):76-82. PubMed ID: 8093857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of intercellular adhesion molecule 1 on small cell lung carcinoma cell lines by gamma-interferon enhances spontaneous and bispecific anti-CD3 x antitumor antibody-directed lymphokine activated killer cell cytotoxicity.
    Azuma A; Yagita H; Matsuda H; Okumura K; Niitani H
    Cancer Res; 1992 Sep; 52(18):4890-4. PubMed ID: 1381273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heregulin induces increase in sensitivity of an erbB-2-overexpressing breast cancer cell type to lysis by lymphokine-activated killer cells.
    Cardillo M; Yankelevich B; Mazumder A; Lupu R
    Cancer Immunol Immunother; 1996 Sep; 43(1):19-25. PubMed ID: 8917631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ICAM-1 and LFA-3 enhance the ability of anti-CD3 mAb to stimulate interferon gamma production in interleukin-2-activated T cells.
    Chong AS; Jiang XL; Scuderi P; Lamas M; Graf LH
    Cancer Immunol Immunother; 1994 Aug; 39(2):127-34. PubMed ID: 7519126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon gamma enhances lymphokine-activated killer cell adhesion but not lysis of head and neck squamous cell carcinoma.
    Scher RL; Carras A; Schwab D; Richtsmeier WJ; Koch WM
    Arch Otolaryngol Head Neck Surg; 1995 Nov; 121(11):1271-5. PubMed ID: 7576474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target lysis by human LAK cells is critically dependent upon target binding properties, but LFA-1, LFA-3 and ICAM-1 are not the major adhesion ligands on targets.
    Quillet-Mary A; Cavarec L; Kermarrec N; Marchiol-Fournigault C; Gil ML; Conjeaud H; Fradelizi D
    Int J Cancer; 1991 Feb; 47(3):473-9. PubMed ID: 1704356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ICAM-1 expression by lung cancer cell lines: effects of upregulation by cytokines on the interaction with LAK cells.
    Melis M; Spatafora M; Melodia A; Pace E; Gjomarkaj M; Merendino AM; Bonsignore G
    Eur Respir J; 1996 Sep; 9(9):1831-8. PubMed ID: 8880099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells.
    Wallgren A; Festin R; Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
    Blood; 1993 Aug; 82(4):1230-8. PubMed ID: 8102559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity.
    Galandrini R; Albi N; Zarcone D; Grossi CE; Velardi A
    Eur J Immunol; 1992 Aug; 22(8):2047-53. PubMed ID: 1379184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon gamma but not tumor necrosis factor alpha decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells.
    Tomita Y; Watanabe H; Kobayashi H; Nishiyama T; Tsuji S; Fujiwara M; Sato S
    Cancer Immunol Immunother; 1992; 35(6):381-7. PubMed ID: 1356627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies anti-CD3, anti-TCR alpha beta and anti-CD2 act synergistically with tumor cells to stimulate lymphokine-activated killer cells and tumor-infiltrating lymphocytes to secrete interferon gamma.
    Chong AS; Staren ED; Scuderi P
    Cancer Immunol Immunother; 1992; 35(5):335-41. PubMed ID: 1382856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphokine-activated killer (LAK)-mediated lysis of sequentially isolated ovarian cancer cell lines.
    Yashar CM; Taylor DD; Gibb RK; Gerçel-Taylor C
    Am J Reprod Immunol; 1997 Dec; 38(6):431-7. PubMed ID: 9412727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.